89
Participants
Start Date
November 7, 2018
Primary Completion Date
July 22, 2021
Study Completion Date
July 22, 2021
Memantine
All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
Placebo (for Memantine)
All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
Penn State Hershey Medical Center, Hershey
University of Florida, Jacksonville
University of Kentucky, Lexington
University of Missouri, Columbia
CoxHealth, Springfield
University of Kansas Medical Center, Kansas City
University of Kansas School of Medicine - Wichita, Wichita
Nerve & Muscle Center of Texas, Houston
Austin Neuromuscular Center, Austin
Phoenix Neurological Associates, Phoenix
UC Irvine, Irvine
Providence Health Sciences, Portland
University of Washington, Seattle
University of Missouri-Columbia
OTHER
University of Kansas Medical Center
OTHER